Enhancing T cell persistence of CAR-redirected T cells in solid tumors

نویسندگان

  • Sonia Guedan
  • Shannon E McGettigan
  • Avery D Posey
  • Jihyun Lee
  • Omkar Kawalekar
  • Prachi R Patel
  • Brian Keith
  • Carl June
چکیده

T cell persistence is likely to promote long-term antitumor effects after adoptive T cell transfer. We have recently shown that incorporation of the ICOS intracellular domain into chimeric antigen receptors (CARs) significantly increased Th17 cell persistence in vivo, compared to CARs with CD28 or 4-1BB intracellular domains [1]. Here, we hypothesized that CD4 and CD8 T cells require distinct cytokine and costimulation signals for optimal persistence. To test this hypothesis, we compared the in vivo antitumor effects and persistence of combined CD4 T cells (bulk or Th17-polarized) and CD8 T cells redirected with CARs containing CD28, 4-1BB or ICOSbased costimulatory domains. Using multiple mouse tumor models, we demonstrate that the ICOS intracellular domain significantly enhanced the in vivo persistence of CAR-expressing CD4 T cells, and that both persistence and tumor infiltration were further enhanced by culturing these cells under Th17-polarizing conditions. Importantly, Th17-polarized CD4 T cells expressing an ICOS-based CAR significantly increased the circulatory persistence of bulk CD8 T cells expressing either CD28or 4-1BBbased CARs. We further demonstrate that the antitumor effect of CAR-expressing CD8 T cells was enhanced when co-injected with ICOS-redirected Th17 cells. Collectively, our data suggest that combining Th17 CD4 T cells redirected with an ICOS-based CAR with CD8 CAR-T cells will enhance their persistence and antitumor efficacy.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

CAR T-cell Therapy of Hematologic Malignancies: An Update in Targeted Antigens

Immunotherapy with genetically engineered T-cells that express the chimeric antigen receptor (CAR) has raised hopes for the treatment of pediatric malignancies. Although CAR T-cell development is on a fast-moving pace and evolution, the context of exploring novel targetable antigens has been neglected. In this review study, we analyze the prominent hematologic antigens targeted by engineered T-...

متن کامل

Design and development of CAR-T cells for cancer therapy

Introduction: Today, treatment with CAR-T cells is accepted as an effective treatment for blood malignancies. CAR-T cells are autologous T cells that are engineered by gene transfer techniques to express a chimeric antigen receptor (CAR). Despite the promising results and the approval of six CAR-T cell products; these products have not yet been approved for solid tumors. In addition, the high c...

متن کامل

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

Targeted T cell immunotherapies using engineered T lymphocytes expressing tumor-directed chimeric antigen receptors (CARs) are designed to benefit patients with cancer. Although incorporation of costimulatory endodomains within these CARs increases the proliferation of CAR-redirected T lymphocytes, it has proven difficult to draw definitive conclusions about the specific effects of costimulator...

متن کامل

Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.

The clinical efficacy of chimeric antigen receptor (CAR)-redirected T cells remains marginal in solid tumors compared with leukemias. Failures have been attributed to insufficient T-cell migration and to the highly immunosuppressive milieu of solid tumors. To overcome these obstacles, we have combined CAR-T cells with an oncolytic virus armed with the chemokine RANTES and the cytokine IL15, rea...

متن کامل

Prospects for combined use of oncolytic viruses and CAR T-cells

With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic option for cancer patients. In parallel, following the favourable results of several clinical trials, adoptive cell transfer using chimeric antigen receptor (CAR)-redirected T-cells is anticipa...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 2  شماره 

صفحات  -

تاریخ انتشار 2014